MacroGenics, Inc. (MGNX) — 分析摘要
MacroGenics, Inc.（MGNX）的市值为236.96百万美元，最近一年的营收同比增长了-0.3%。净利润率为-49.9%。当前市盈率为-16.2倍。
核心要点
- 营收同比变化-0.3%
- 净利润率-49.9%
- 市盈率-16.2倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，MGNX的营收增长为-0.3%，市盈率为-16.2倍。
MacroGenics, Inc. (MGNX)
前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -2.7x — 盈利不足以覆盖利息支出
营业利润率为 -29.5% — 经营亏损显著
最新报表显示自由现金流为负。
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
293
总部
Rockville, MD
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。